Medicines for All uses chemistry to improve global health
Richmond—Not far from where highways I-95 and I-64 meet in Richmond, Virginia, there’s a quiet biotech park…
Cramer: I asked tech insiders what to buy. They said Eli Lilly
Jim Cramer said Monday that even tech-focused people think the world of Eli Lilly stock, with one predicting…
Patient dies in Bristol Myers Squibb investigational CAR-T therapy trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
DEA Drug Take Back Day set for Saturday to promote safe medication disposal
KANSAS CITY, Mo. — The DEA’s National Drug Take Back event his Saturday offers a safe way to…
Novo’s CagriSema shows 25% weight loss in women
Novo on Tuesday said its next-generation obesity drug, CagriSema, showed 25% weight loss on average among adult women…
Young men are injecting testosterone to be more ‘masculine’
For years, Aiden* didn’t think his naturally skinny figure represented who he was. Athletic but slight, he felt…
Launch price of new medicines dropped very slightly in 2025
Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly…
Two deaths linked to bootleg versions of unapproved weight loss drug
A costly jab. As more information is coming to light about one of the newest’s weight loss drug,…
Why patients stop taking their medications
During my years as a clinical pharmacist, I thought I understood why patients stopped taking long-term medications —…
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
UnitedHealth Group (UNH) earnings Q3 2026
UnitedHealth Group signage on the floor of the New York Stock Exchange on April 21, 2025. Michael Nagle…
Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…